Literature DB >> 34116440

Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum.

Francesco Bavato1, Flurin Cathomas2, Federica Klaus2, Karoline Gütter2, Christian Barro3, Aleksandra Maceski3, Erich Seifritz4, Jens Kuhle3, Stefan Kaiser5, Boris B Quednow4.   

Abstract

BACKGROUND: Schizophrenia (SZ) and major depressive disorders (MDD) have been frequently linked to anatomical brain alterations. However, the relationship between brain pathology, inflammation and clinical symptoms in these disorders is still unclear. Thus, by applying novel blood markers of neuroaxonal integrity such as neurofilament light chain (NfL), we can now address main issues in psychiatric research and potentially offer innovative diagnostic tools toward better clinical characterizations and monitoring in both SZ and MDD.
METHODS: NfL levels were measured in serum of 44 patients with SZ and in 41 patients with MDD applying single molecule array technology and compared to a healthy norm population. Main inflammatory markers (C- reactive protein, interleukins IL-6 and IL-10) were measured to define patients with inflammatory phenotype. The Digit Symbol Substitution Task (DSST) and the Letter-Number-Sequencing Task were performed to estimate cognitive function in both groups.
RESULTS: NfL levels in MDD group (but not in SZ group) were significantly higher than reference values of healthy norm population. A higher than expected proportion of patients with NfL levels above age-specific cut-off values was observed in both SZ and MDD groups. No correlation was observed between NfL and inflammatory markers. A negative correlation between DSST and NfL-values was observed in patients with MDD.
CONCLUSIONS: Both SZ and MDD showed elevated serum levels of NfL, which were independent from inflammatory markers but associated with cognitive performance.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cognition; Depression; Inflammation; Neurofilament light chain; Schizophrenia

Year:  2021        PMID: 34116440     DOI: 10.1016/j.jpsychires.2021.05.072

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

1.  Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment: A systematic review and meta-analysis.

Authors:  Jing Zhang; Hongjiang Cheng; Wei Liu; Huimin Li; Yi Song; Longbin Jia
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

2.  Serum Neurofilament Light Predicts 6-Month Mental Health Outcomes in a Cohort of Patients With Acute Ischemic Stroke.

Authors:  Duo-Zi Wang; Fu-Qiang Guo; Lei Guo; Shu Yang; Neng-Wei Yu; Jian Wang; Jian-Hong Wang
Journal:  Front Psychiatry       Date:  2022-02-07       Impact factor: 4.157

3.  Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine ("Ecstasy") induced cytoskeletal damage.

Authors:  F Bavato; B B Quednow; S Stamatakos; C M Yde Ohki; E Seifritz; P Romualdi; E Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2022-04-14       Impact factor: 3.850

4.  Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).

Authors:  Tommaso F Nicoletti; Salvatore Rossi; Maria Gabriella Vita; Alessia Perna; Gisella Guerrera; Federica Lino; Chiara Iacovelli; Daniele Di Natale; Anna Modoni; Luca Battistini; Gabriella Silvestri
Journal:  J Neurol       Date:  2022-05-16       Impact factor: 6.682

5.  Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia.

Authors:  Flurin Cathomas; Stefan Kaiser; Federica Klaus; Karoline Guetter; Rebecca Schlegel; Tobias R Spiller; Erich Seifritz
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.